Bottom line: no benefit. Double-Blind Phase III Trial of Adjuvant Chemotherapy With and Without Bevacizumab in Patients With Lymph Node–Positive and High-Risk Lymph Node–Negative Breast Cancer (E5103): Journal of Clinical Oncology: Vol 0, No 0
Adjuvant E5103 3-arm trial in ~5K early #BreastCancer pts: AC-T vs. same w/ bev during or during & after chemo. No difference in efficacy, more CHF w/ bev, very high bev early d/c rates due to toxicity. #bcsm